AER 1548439 is a spontaneous case, was received on 04/Mar/2015 from a consumer and concerns a 62 year old 
female patient who developed progressive multifocal leukoencephalopathy (PML) while treated with rituximab 
(Rituxan).
The patient's  medical history included hodgkins lymphoma, two stem cell transplants, the first from herself and the 
second from her sister. She developed graft vs host disease which affected her skin and developed severe rash 
and pustules.  She had no history of drug, alcohol abuse, smoking,  drug allergies or family history of cancer. No 
concurrent conditions, concomitant medication or past drugs were reported.
On 11/Jun/2014, the patient started with intravenous (IV) rituximab infusion (form and frequency not reported) for 
graft-versus-host disease (unapproved indication). On 19/Jun/2014, 26/Jun/2014 and 03/Jul/2014, she received 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 103 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
Preferred Term ( MedDRA  Version: 17.1 ReC
next 3 dose of rituximab. It was reported that, she responded well to treatment and the skin rash cleared up. On 
03/Jul/2014, therapy with rituximab was discontinued. Later, in /Sep/2014, she became clumsy and had loss of 
limbs. In /Dec/2014, her nuclear magnetic resonance imaging (MRI) and biopsy brain were performed which 
showed that she had PML. On (b) (6)  she died due to PML.
The reporter did not report causality of PML with rituximab.
No further information was reported.